Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cooleys Anemia Foundation

Perspective on the power of insight

In this issue of Perspective magazine, our in-house insight experts unite to reveal the best practical tools, tips and knowledge for harnessing insight to empower your customers and inspire innovation.

Blue Latitude Health

Impact of data sharing

With the General Data Protection Regulation (GDPR) on the horizon, the Cambridge Analytica scandal has provided a stark reminder of the importance of data protection laws.

Dovetail

A critical juncture for clinical data management

Data management functions are handling a much higher volume and diversity of data in response to the increasing scope and demands of global drug development programmes. Real-world data and evidence,...

Celgene building

Celgene boosts CAR-T stake again with Bluebird Bio deal

The US biotech could receive $70m in development milestones for the candidate

- PMLiVE

Health insurers will test blockchain for data handling

Aims to make health records more accurate and reliable

- PMLiVE

Six degrees of participation

Exploring the ongoing journey to patient empowerment and examining how pharma can play a part in more participatory models of care

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

Healthcare sector ‘lacks awareness’ of cybersecurity threats

RAE report suggests medical devices could be prone to cyber attacks

The rise of real-world evidence

Demonstrating efficacy and value requires more than clinical trial data

Joined-up thinking on anaemia

Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated.

Dovetail

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

- PMLiVE

Shaky mid-stage data won’t halt Celgene’s plans for Otezla

The US biotech will continue to test the drug in patients with UC and Behçet’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links